2011年醫療藥物產業重大趨勢 - 處方藥銷售概況 是由出版商Datamonitor在2011年02月所出版的。
這份英文市場調查報告書包含Pages: 72 價格從美金3800起跳。
全球主要國家（美國、法國、德國、義大利、西班牙、英國、日本、澳大利亞、巴西、俄羅斯、中國及印度）處方藥於2009年之總銷售為5550億美金，較上年成長6.3%，以2005年為起算點之複合年均成長也增加5.6%。
本報告為，關注上述12國之處方藥市場，並匯整各種治療領域之銷售成長趨勢、各國知名品牌之評估、全球及各國大型企業簡介、對象年齡層、分子結構、原料、地區、治療領域、調配方式區隔之銷售預測等特殊調查資訊，以下列摘要形式闡述。
實施概要
- 簡介
- 策略範圍及重點
- 重要觀點
- 主要12國之醫療藥物市場規模
- 主要12國之代表治療領域
- 主要12國之代表處方藥品牌
- 主要12國之大型製藥公司
- 2015年止大型製藥公司銷售成長之驅力及阻力
- 相關報告
- 預計出版報告
處方藥銷售之歷史分析
- 醫療藥物市場規模
- 美國雖為全球醫療藥物最大市場，但於2015年間將會衰退
- 歐洲受成本控制政策些微成長
- 非專利藥產業於重視品牌之日本快速成長
- 小規模之澳大利亞醫藥產業著手於成本縮減之政策
- 新興市場展現最大之成長率
- 代表治療領域
- 因與非專利藥激烈競爭，預計中樞神經系統（CNS）、心血管藥物市場於2015年間將會衰退
- 代謝類、腫瘤治療市場受生物製劑銷售增加牽引
- 中藥為成長率最高之產品群
- 代表處方藥品牌
- Lipitor受專利失效打擊，使銷售銳減
- Plavix為產業領先之抗血栓，並受豐富數據支持
- Nexium之成長如黃金標準之地位，並廣受病患服用，但預測及銷售將會減少
- 大型製藥公司
- Pfizer
- Merck & Co.
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Sanofi-Aventis
- Roche
- Johnson & Johnson
- Eli Lilly
- 武田藥品工業
處方藥銷售預測分析
- 定義
- 50間製藥公司於2015年止全球銷售拓展之驅力及阻力
參考文獻
附錄
圖表
Abstract
Introduction
Prescription pharmaceutical sales in the world’s major markets (US,
France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China
and India) totaled $555bn in 2009, having grown by 6.3% during 2008-09,
and at a compound annual growth rate (CAGR) of 5.6% between 2005 and
2009.
Features and benefits
• Examines the prescription pharmaceutical sales growth trends across the
various different therapy areas
• Assesses the leading prescription pharmaceutical brands across the
each of the 12 major pharma markets
• Profiles the leading multinational and domestic pharma companies
operating in each of the 12 major pharma markets
• Analyzes the forecast sales according to lifecycle stage of drug,
molecule type, source of drug, geographical market, therapy area and
formulation
Highlights
The US prescription pharmaceutical market generated half (50.3%) of the sales
of the 12 markets analyzed, with $279bn in 2009, with sales having grown by
5.0% (CAGR, 2005-09) and 5.5% (2008-09). However, future sales
growth will be shaped by three key events: the US economic downturn,
healthcare reform and the patent cliff.
Pharma is set to loose approximately $108bn in sales due to the patent cliff
during 2010-15, while the industry is also feeling the affect of the
recent global economic downturn. However, Pharma is implementing a number of
strategies to drive sales and profitability going forward: product innovation,
diversification and cost-containment.
Growth in the emerging markets is driven by their rapidly growing economies
and populations; expansion of healthcare systems and health insurance
policies, increasing access to drugs; and the emergence of middle classes with
disposable incomes, who are more likely to spend money on branded generics and
branded pharmaceuticals.
Your key questions answered
• Evaluate the evolving prescription pharmaceutical landscape and how
this is set to impact Pharma out to 2015
• Quantify the size and growth of the 12 major pharmaceutical markets,
analyzing key therapy areas, brands and companies
• Assess drivers and resistors of the prescription pharmaceutical
market
Table of Contents
Executive Summary
Introduction
Strategic scoping and focus
Key Findings
Pharmaceutical market size in the 12 major markets
Leading therapy areas in the 12 major markets
Leading prescription pharmaceutical brands in the 12 major markets
Leading pharmaceutical companies in the 12 major markets
Global drivers and resistors for sales growth of the leading pharmaceutical
companies out to 2015
Related reports
Upcoming related reports
2. HISTORICAL PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Pharmaceutical Market Size
The US pharmaceutical market while the largest will decline through 2015
Cost-containment policies throughout Europe translate in modest growth
Brand loyal Japan aims to boost its generics industry
Australia’s small pharmaceutical market is also undertaking
cost-cutting measures
The emerging markets showed the fastest growth rates
Leading Therapy Areas
The CNS and cardiovascular markets will experience sales declines out to 2015
due to increasing generic competition
Metabolic, oncology and oncology markets driven by biologic sales growth
Chinese medicines are the fastest growing drug group
Leading Pharmaceutical Brands
Lipitor is to experience a dramatic loss in sales due to its looming patent
expiry
Plavix is the industry-leading antithrombotic and is supported by a wealth of
post-launch data
Nexium growth is attributed to its gold standard status and extensive patient
switching, but sales are forecast to decline
Leading Pharmaceutical Companies
Pfizer
Merck & Co.
AstraZeneca
GlaxoSmithKline
Novartis
Sanofi-Aventis
Roche
Johnson & Johnson
Eli Lilly
Takeda
3. FORECAST PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Definitions
Global drivers and resistors for sales growth of the top 50 pharmaceutical
companies out to 2015
The top 50 pharmaceutical companies (excluding generics companies) will
experience sales growth of only 1.1% per year out to 2015
Expiries will only just be offset by newly launched and core drugs
The pharmaceutical industry' s biologic focus is growing
The industry will derive the majority of its sales from external products by
2015
Growth in global markets will more than offset sales decline in the US
Secondary care therapy areas are becoming a priority for pharma
Injectable drugs are set to drive market growth
Blockbuster drug sales will decline during 2010-15
4. BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Datamonitor prescription pharmaceutical definition and therapy area
classification
